Clear Harbor Asset Management LLC Grows Position in Becton, Dickinson and Company $BDX

Clear Harbor Asset Management LLC boosted its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 371.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,709 shares of the medical instruments supplier’s stock after acquiring an additional 17,105 shares during the period. Clear Harbor Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $4,213,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Imprint Wealth LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter worth approximately $25,000. Steph & Co. increased its holdings in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after buying an additional 65 shares during the period. Cornerstone Planning Group LLC increased its holdings in Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 139 shares during the period. Accredited Wealth Management LLC raised its stake in Becton, Dickinson and Company by 77.8% in the third quarter. Accredited Wealth Management LLC now owns 160 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 70 shares in the last quarter. Finally, WPG Advisers LLC lifted its holdings in Becton, Dickinson and Company by 64.2% during the fourth quarter. WPG Advisers LLC now owns 156 shares of the medical instruments supplier’s stock worth $30,000 after buying an additional 61 shares during the period. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on BDX. Piper Sandler dropped their target price on Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. TD Cowen decreased their price objective on Becton, Dickinson and Company from $189.00 to $163.00 and set a “hold” rating for the company in a research note on Monday, May 4th. Jefferies Financial Group dropped their price objective on Becton, Dickinson and Company from $220.00 to $190.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. The Goldman Sachs Group cut their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Finally, Stifel Nicolaus reduced their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Seven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $183.64.

Becton, Dickinson and Company Stock Performance

Shares of BDX opened at $147.13 on Monday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35. The stock has a fifty day moving average price of $151.63 and a 200-day moving average price of $176.99. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market cap of $40.54 billion, a PE ratio of 37.25, a P/E/G ratio of 10.42 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.The firm had revenue of $4.71 billion for the quarter, compared to the consensus estimate of $4.67 billion. During the same period in the previous year, the business earned $3.35 EPS. The firm’s revenue for the quarter was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Equities research analysts predict that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Investors of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.